XML 31 R21.htm IDEA: XBRL DOCUMENT
v3.20.2

Financial instruments (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2020
Financial Instruments - additional disclosure [abstract] |
Fair value by hierarchy |
|  | Level 1 |  | Level 2 |  | Level 3 |  | Total |
(USD millions) |  | Jun 30, 2020 |  | Dec 31, 2019 |  | Jun 30, 2020 |  | Dec 31, 2019 |  | Jun 30, 2020 |  | Dec 31, 2019 |  | Jun 30, 2020 |  | Dec 31, 2019 |
Marketable securities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Debt securities |  |  |  |  |  | 24 |  | 24 |  |  |  |  |  | 24 |  | 24 |
Fund investments |  | 33 |  | 37 |  |  |  |  |  |  |  |  |  | 33 |  | 37 |
Total marketable securities |  | 33 |  | 37 |  | 24 |  | 24 |  |  |  |  |  | 57 |  | 61 |
Derivative financial instruments |  |  |  |  |  | 136 |  | 102 |  |  |  |  |  | 136 |  | 102 |
Total marketable securities and derivative financial instruments |  | 33 |  | 37 |  | 160 |  | 126 |  |  |  |  |  | 193 |  | 163 |
Long-term financial investments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Debt and equity securities |  | 904 |  | 976 |  |  |  |  |  | 539 |  | 581 |  | 1 443 |  | 1 557 |
Fund investments |  |  |  |  |  |  |  |  |  | 235 |  | 233 |  | 235 |  | 233 |
Contingent consideration receivables |  |  |  |  |  |  |  |  |  | 444 |  | 399 |  | 444 |  | 399 |
Total long-term financial investments |  | 904 |  | 976 |  |  |  |  |  | 1 218 |  | 1 213 |  | 2 122 |  | 2 189 |
Associated companies at fair value through profit or loss |  |  |  |  |  |  |  |  |  | 175 |  | 186 |  | 175 |  | 186 |
Contingent consideration payables |  |  |  |  |  |  |  |  |  | – 1 039 |  | – 1 036 |  | – 1 039 |  | – 1 036 |
Other financial liabilities |  |  |  |  |  |  |  |  |  | – 20 |  | – 29 |  | – 20 |  | – 29 |
Derivative financial instruments |  |  |  |  |  | – 126 |  | – 185 |  |  |  |  |  | – 126 |  | – 185 |
Total financial liabilities at fair value |  |  |  |  |  | – 126 |  | – 185 |  | – 1 059 |  | – 1 065 |  | – 1 185 |  | – 1 250 |
Disclosure of detailed information about borrowings |
Coupon |  | Currency |  | Nominal amount (USD millions) |  | Maturity year |  | Issuer |  | Issue price |  | Carrying value Jun 30, 2020 (USD millions) |
1.75% |  | USD |  | 1 000 |  | 2025 |  | Novartis Capital Corporation, New York, United States |  | 99.852% |  | 996 |
2.00% |  | USD |  | 1 250 |  | 2027 |  | Novartis Capital Corporation, New York, United States |  | 99.909% |  | 1 245 |
2.20% |  | USD |  | 1 500 |  | 2030 |  | Novartis Capital Corporation, New York, United States |  | 99.869% |  | 1 492 |
2.75% |  | USD |  | 1 250 |  | 2050 |  | Novartis Capital Corporation, New York, United States |  | 97.712% |  | 1 213 |

X
- Definition The entire disclosure for fair value measurement. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 13 -IssueDate 2019-01-01 -Section Disclosure -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2019-en-r&doctype=Standard&dita_xref=IFRS13_g91-99_TI -URIDate 2019-03-27 + Details
Name: | ifrs-full_DisclosureOfFairValueMeasurementExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock
Namespace Prefix: | nvs_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_FinancialInstrumentsAdditionalDisclosureAbstract
Namespace Prefix: | nvs_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration